Perspective Therapeutics (CATX) Common Equity (2011 - 2026)

Perspective Therapeutics (CATX) has 16 years of Common Equity data on file, last reported at $347.4 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 22.06% year-over-year to $347.4 million; the trailing twelve-month figure through Mar 2026 stood at $347.4 million (up 22.06% YoY), and the FY2025 full-year result was $207.0 million, down 28.77% from the prior year.
• Common Equity grew to $347.4 million in Q1 2026, from $207.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $347.4 million in Q1 2026 to a low of $54.6 million in Q4 2022.
• A 5-year average of $186.7 million and a median of $207.0 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 286.63% in 2024 and fell 28.77% in 2025, its largest moves.
• Tracing CATX's Common Equity over 5 years: stood at $54.6 million in 2022, then jumped by 37.58% to $75.2 million in 2023, then surged by 286.63% to $290.7 million in 2024, then slipped by 28.77% to $207.0 million in 2025, then surged by 67.82% to $347.4 million in 2026.
• Business Quant data shows CATX's Common Equity at $347.4 million in Q1 2026, $207.0 million in Q4 2025, and $242.2 million in Q3 2025.